Large Cap Biopharma Stock Performance YoY from J.P.Morgan Conference
The market recovered slightly today from yesterday’s “Trump storm” attacking drug prices. The IBB rose 0.36% and the XBI rose 1.56% . The healthcare sector overall was flat.
Selected stocks that continued their upward trend from earlier this week are: Array Biopharma (ARRY) up 7.3% -Five year high, bluebird bio (BLUE) up 1.77%, Clovis Oncology (CLVS), Incyte (INCY) up 1.96%, Intercept Pharmaceuticals up 4.2%, Merck (MRK) up 0.94% and Seattle Genetics (SGEN) up 5.4%.
Here is my Large Cap Biopharmaceutical Performance Summary for 2016 at this time last year (1/7/16) at the Conference.
Here is a comparison of these 8 large cap biopharmaceutical companies’ stocks performance YoY 1/7/16 vs 1/12/17. Abbvie (ABBV) was up 7% and compared to the IBB down 7.3%.
Abbvie (ABBV) $57.21 to 61.28–Up 7%
Alexion (ALXN) $174.37 to 137.35
Amgen (AMGN) $152.98 to 155.36
Biogen (BIIB) $284.01 to 287.77
Bristol-MyersS (BMY) $65.27 to 56.55
Celgene (CELG)$111.89 to 117.08- Up 4.5%
Gilead Sciences (GILD) $96.25 to 73.36
Regeneron (REGN) $501.96 to 364.44, down 27.5%
IBB $302 to $280,high of $326 on 1/1/16; low of $244 on 2/11/16
Top gainers YoY are: ABBV, CELG and AMGN.
Top losers YoY are: ALXN, REGN and GILD.